Romainville, October 5th, 2009 - Cellectis bioresearch, a specialist in genome customization and a subsidiary of
Cellectis S.A. (Alternext: ALCLS), today launched cGPS® CHO-K1 duo – its third research kit now available. cGPS®
CHO-K1 duo enables the targeted integration of several genes or regulatory elements at two independent genomic
sites in the CHO-K1 cell line.
"The cGPS® CHO-K1 duo kit enables industrial high-throughput screening platforms to screen drug candidates against difficult-to-express targets", commented Luc Selig, VP Sales & Marketing at Cellectis bioresearch. "This new product fits perfectly into our cGPS® line, which brings speed, ease-of-use and robust performances to processes that were previously lengthy, burdensome and erratic".
The discovery of a new drug usually involves screening hundreds of thousands of compounds against cells expressing the target of interest. Many targets (such as membrane receptors) cannot be adequately over-expressed, due to their excessive toxicity or a requirement for the assembly of several subunits. The cGPS® CHO-K1 duo kit developed by Cellectis bioresearch enables stable and regulated expression of several protein subunits in the CHOK1 cell line, the most frequently used for screening. It also enables the integration of an inducible expression system, which can attenuate the toxic effects of certain drug targets.
The targeted integration kit ranges - cGPS® (cellular Genome Positioning System) and cGPS® Custom - are available for purchase at www.cellectis-bioresearch.com.
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of Cellectis SA (Alternext: ALCLS) in June 2008. It provides life science researchers with genome customization kits for rapid, efficient gene integration at a precise genomic position in a given cell type.
About Cellectis S.A.
Cellectis S.A. is a world leader in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in vivo genome surgery addressing the therapeutic, agrofood, biomanufacturing and research sectors. Worldwide, Cellectis has entered into more than 50 agreements with major players in the pharma, biotech and agrobiotech industries and has over 20 collaborations with academic research groups. To date, Cellectis has raised over €50 million in both equity operations and public financing and is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS). For more information on Cellectis, visit our website: www.cellectis.com
"The cGPS® CHO-K1 duo kit enables industrial high-throughput screening platforms to screen drug candidates against difficult-to-express targets", commented Luc Selig, VP Sales & Marketing at Cellectis bioresearch. "This new product fits perfectly into our cGPS® line, which brings speed, ease-of-use and robust performances to processes that were previously lengthy, burdensome and erratic".
The discovery of a new drug usually involves screening hundreds of thousands of compounds against cells expressing the target of interest. Many targets (such as membrane receptors) cannot be adequately over-expressed, due to their excessive toxicity or a requirement for the assembly of several subunits. The cGPS® CHO-K1 duo kit developed by Cellectis bioresearch enables stable and regulated expression of several protein subunits in the CHOK1 cell line, the most frequently used for screening. It also enables the integration of an inducible expression system, which can attenuate the toxic effects of certain drug targets.
The targeted integration kit ranges - cGPS® (cellular Genome Positioning System) and cGPS® Custom - are available for purchase at www.cellectis-bioresearch.com.
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of Cellectis SA (Alternext: ALCLS) in June 2008. It provides life science researchers with genome customization kits for rapid, efficient gene integration at a precise genomic position in a given cell type.
About Cellectis S.A.
Cellectis S.A. is a world leader in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in vivo genome surgery addressing the therapeutic, agrofood, biomanufacturing and research sectors. Worldwide, Cellectis has entered into more than 50 agreements with major players in the pharma, biotech and agrobiotech industries and has over 20 collaborations with academic research groups. To date, Cellectis has raised over €50 million in both equity operations and public financing and is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS). For more information on Cellectis, visit our website: www.cellectis.com
